Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
0 hedge funds and large institutions have $0 invested in Talis Biomedical Corporation Common Stock in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $26 → $0 (-$26)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
-$26 |
TLIS Hedge Fund Activity: Q1 2025 in Review
0 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q1 2025, worth a combined $0 — down 100% from $26 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of TLIS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Synergy Asset Management, exiting entirely with an estimated $26 sold.
- 0 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q1 2025, down from 1 in Q4 2024.
- Funds reported $0 of Talis Biomedical Corporation Common Stock stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Talis Biomedical Corporation Common Stock positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest Talis Biomedical Corporation Common Stock seller in Q1 2025 was Synergy Asset Management, an estimated $26 sold.
Based on aggregated 13F filings for Q1 2025.